CD10

Product List

As an emerging target in the field of CAR-T cell therapy, CD10 has been reported to be associated with the development of a variety of tumors. Creative Biolabs offers a wide range of CD10 CAR products based on years of in-depth research and expertise in CAR-T therapy. The following is a brief list of product categories, you can search for keywords to get the CD10 CAR product you want.

Background

CD10, also known as "common acute lymphoblastic leukemia antigen", is a lymphatic follicular centrocyte marker. Positive for germinal center follicular lymphoma, Burkitt lymphoma, chronic myeloid leukemia and TDT⁺ lymphocytic leukemia. In the early stages of adult bone marrow, precursor lymphocytes, immature B cells, and normal tonsils and germinal centers of lymphoid tissue are also positive.

Fig.1 CD10 signaling pathways in breast carcinoma.¹

Associated Diseases

Germinal Center Follicular Lymphoma

Burkitt Lymphoma

Chronic Myeloid Leukemia

TDT+ Lymphocytic Leukemia

B Cell Acute Lymphoblastic Leukemia

Anti-CD10 CAR-T Services

CD10 CAR Design & Construction

Creative Biolabs offers different kinds of CAR design and build. In addition to conventional CAR, we also offer the universal CAR T cell platform (UniCAR). The UniCAR can be adjusted by adapters, quickly reaching the target, and dissociating quickly (high shutdown rate).

Fig.2 Schematic diagram of the targeting CD10 CAR T construction.² A: Schematic diagram of a universal CAR T cell platform. B: Schematic diagram of the structure of B anti-CD10.

Anti-CD10 CAR-T In Vitro Assays

Anti-CD10 CAR-T Expression Test

Analyzing the expression level of the target protein is a critical step in the overall CAR cell therapy process. At Creative Biolabs, our scientists offer different assays for your protein expression levels, including SDS-PAGE, loss cytometry, western blotting, and more, based on high-level scientific research.

Fig.3 Analysis of CD10 target molecule by SDS-PAGE and western blotting.²

Anti-CD10 CAR-T Cytokine Release Test

Detecting the ability of anti-CD10 UniCAR T cells to release pro-inflammatory factors is an important part of studying T cell function. As shown in Figure 4, CD10 UniCAR T cells were able to significantly increase IFNγ, TNF, and IL-2 production.

Fig.4 Detection of the level of cytokines released from CD10 UniCAR T cells by ELISA.²

Anti-CD10 CAR-T In Vitro Cytotoxicity Assay

To investigate the specific cytotoxic activity of anti-CD10 UniCAR T cells, Creative Biolabs offers in vitro cytotoxicity assays. Nalm-6 Luc cells and anti-CD10 UniCAR T cells were incubated together as shown in the figure below. CD10 UniCAR T cytotoxicity is assessed using a luminescence assay. The results showed that anti-CD10 UniCAR T cells specifically killed CD10-expressing leukemia cells.

Fig.5 Anti-CD10 UniCAR T cell cytotoxicity in Nalm-6 Luc cells.²

Anti-CD10 CAR-T In Vivo Assays

In addition to CD10 CAR-T in vitro assay service, Creative Biolabs' one-stop CAR-T therapy development platform also provides you with preclinical in vivo assay services. These include the construction of xenograft animal models, effectiveness testing of CD10 CAR-T cells, strategies for utilizing cytokine release syndrome, in vivo efficacy testing of CD10 CAR-T, and in vivo toxicity evaluation, and so on. You can click on the link above for more information!

References

1. Jana, S.H.; et al. "CD10-A new prognostic stromal marker in breast carcinoma, its utility, limitations and role in breast cancer pathogenesis." Indian J Pathol Microbiol. (2014) 57:530-6.
2. Mitwasi, Nicola.; et al. "Targeting CD10 on B-Cell leukemia using the universal CAR T-cell platform (UniCAR)." International journal of molecular sciences. (2022) 23,9 4920.